BioXcel Therapeutics, Inc. (BTAI) › Cost of RevenueBioXcel Therapeutics, Inc. (BTAI) — Cost of RevenueAnnual figures by period end, from SEC filings.2022-12-31: $20.0K2023-12-31: $1.26M2024-12-31: $2.14M2025-12-31: $164.0K$164.0K2022-12-31Cost of Revenue (USD)2025-12-31Period endedCost of RevenueChange YoYSource filing2025-12-31$164.0K-92.3%2026-03-27From 2025-01-012024-12-31$2.14M+70.1%2026-03-27From 2024-01-012023-12-31$1.26M+6200.0%2025-03-28From 2023-01-012022-12-31$20.0K—2024-03-22From 2022-01-01Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)